TW200526603A - Fused-aryl and heteroaryl derivatives and methods of their use - Google Patents
Fused-aryl and heteroaryl derivatives and methods of their use Download PDFInfo
- Publication number
- TW200526603A TW200526603A TW093131005A TW93131005A TW200526603A TW 200526603 A TW200526603 A TW 200526603A TW 093131005 A TW093131005 A TW 093131005A TW 93131005 A TW93131005 A TW 93131005A TW 200526603 A TW200526603 A TW 200526603A
- Authority
- TW
- Taiwan
- Prior art keywords
- ethyl
- esi
- cyclohexanol
- ylethyl
- naphthyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 726
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 20
- 208000002193 Pain Diseases 0.000 claims abstract description 59
- 230000036407 pain Effects 0.000 claims abstract description 55
- 208000024891 symptom Diseases 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 230000001457 vasomotor Effects 0.000 claims abstract description 30
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 20
- 201000001880 Sexual dysfunction Diseases 0.000 claims abstract description 16
- 231100000872 sexual dysfunction Toxicity 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 230000002496 gastric effect Effects 0.000 claims abstract description 14
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 12
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 11
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 9
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 9
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 9
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims abstract description 6
- -1 methylenedioxy, benzyloxy Chemical group 0.000 claims description 799
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 408
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 181
- WVSAVJBOUPZGJG-UHFFFAOYSA-N cyclohexanol;dihydrochloride Chemical compound Cl.Cl.OC1CCCCC1 WVSAVJBOUPZGJG-UHFFFAOYSA-N 0.000 claims description 166
- 150000001875 compounds Chemical class 0.000 claims description 154
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 95
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 93
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 87
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 46
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 206010060800 Hot flush Diseases 0.000 claims description 20
- 125000001624 naphthyl group Chemical group 0.000 claims description 20
- 150000001412 amines Chemical class 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 230000009103 reabsorption Effects 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 230000009245 menopause Effects 0.000 claims description 17
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 13
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000001041 indolyl group Chemical group 0.000 claims description 12
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 208000025609 Urogenital disease Diseases 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 10
- 206010021639 Incontinence Diseases 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 8
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 4
- GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 3
- 206010003439 Artificial menopause Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000035946 sexual desire Effects 0.000 claims description 2
- 208000022925 sleep disturbance Diseases 0.000 claims description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 1
- WDECIBYCCFPHNR-UHFFFAOYSA-N Chrysene Natural products C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 claims 1
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 208000035475 disorder Diseases 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 7
- 208000000921 Urge Urinary Incontinence Diseases 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000000407 monoamine reuptake Effects 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 151
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 124
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 116
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 87
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 74
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 73
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 69
- 239000002253 acid Substances 0.000 description 60
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 57
- 229960000583 acetic acid Drugs 0.000 description 55
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 52
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 40
- 229910052704 radon Inorganic materials 0.000 description 39
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 39
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 31
- 229910052722 tritium Inorganic materials 0.000 description 31
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 28
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 27
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 26
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 26
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 22
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 19
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 18
- 229960002748 norepinephrine Drugs 0.000 description 18
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 18
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 17
- RBAMGJNJQHNIJX-UHFFFAOYSA-N cyclobutanol;dihydrochloride Chemical compound Cl.Cl.OC1CCC1 RBAMGJNJQHNIJX-UHFFFAOYSA-N 0.000 description 17
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 16
- HFNCOTSLOKKPHU-UHFFFAOYSA-N cyclohexanol;hydrochloride Chemical compound Cl.OC1CCCCC1 HFNCOTSLOKKPHU-UHFFFAOYSA-N 0.000 description 15
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 15
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 15
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 14
- WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 14
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 14
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 14
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 14
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 14
- OANNCEVIYONFOC-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=CC(Cl)=C1 OANNCEVIYONFOC-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 13
- UBWBVRSSIHWAQL-UHFFFAOYSA-N 2-tert-butylpiperidine-1-carboxylic acid Chemical compound CC(C)(C)C1CCCCN1C(O)=O UBWBVRSSIHWAQL-UHFFFAOYSA-N 0.000 description 12
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 238000007796 conventional method Methods 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 10
- HYEPAONYVPIVMR-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=CC(OC(F)(F)F)=C1 HYEPAONYVPIVMR-UHFFFAOYSA-N 0.000 description 10
- RNAFFCDDPQAGDR-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=CC(Br)=C1 RNAFFCDDPQAGDR-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 10
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 10
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- 239000005971 1-naphthylacetic acid Substances 0.000 description 9
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 9
- UPFWHRIMKFAUDL-UHFFFAOYSA-N 2-(3-chloro-4-phenylmethoxyphenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1Cl)=CC=C1OCC1=CC=CC=C1 UPFWHRIMKFAUDL-UHFFFAOYSA-N 0.000 description 9
- SLOVAXRWKHCZHG-UHFFFAOYSA-N Cl.Cl.CCCCCCO Chemical compound Cl.Cl.CCCCCCO SLOVAXRWKHCZHG-UHFFFAOYSA-N 0.000 description 9
- 208000033830 Hot Flashes Diseases 0.000 description 9
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 9
- 229940076279 serotonin Drugs 0.000 description 9
- JKIGHOARKAIPJI-UHFFFAOYSA-N (3,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C(Cl)=C1 JKIGHOARKAIPJI-UHFFFAOYSA-N 0.000 description 8
- ZWAMJENZBDVVDH-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperidin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CCCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 ZWAMJENZBDVVDH-UHFFFAOYSA-N 0.000 description 8
- AGUXIBJEWUEHLS-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=CC(C(F)(F)F)=C1 AGUXIBJEWUEHLS-UHFFFAOYSA-N 0.000 description 8
- UQXFLQAZOOTXEZ-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[4-(trifluoromethoxy)phenyl]acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=C(OC(F)(F)F)C=C1 UQXFLQAZOOTXEZ-UHFFFAOYSA-N 0.000 description 8
- QJIBYGWDEICULP-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-naphthalen-2-ylacetic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(C(=O)O)C1(O)CCCCC1 QJIBYGWDEICULP-UHFFFAOYSA-N 0.000 description 8
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000004305 biphenyl Substances 0.000 description 8
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 229960003424 phenylacetic acid Drugs 0.000 description 8
- 239000003279 phenylacetic acid Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 7
- DYCDMMQKBYPTKF-UHFFFAOYSA-N 2,3,4,5-tetrachloro-2H-pyran Chemical compound ClC=1C(=C(C(OC=1)Cl)Cl)Cl DYCDMMQKBYPTKF-UHFFFAOYSA-N 0.000 description 7
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 7
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 7
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 7
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- VIBOGIYPPWLDTI-UHFFFAOYSA-N 2-naphthylacetic acid Chemical compound C1=CC=CC2=CC(CC(=O)O)=CC=C21 VIBOGIYPPWLDTI-UHFFFAOYSA-N 0.000 description 6
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 6
- STWODXDTKGTVCJ-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1C1CCNCC1 STWODXDTKGTVCJ-UHFFFAOYSA-N 0.000 description 6
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001499 aryl bromides Chemical class 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- 125000000068 chlorophenyl group Chemical group 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 150000007857 hydrazones Chemical class 0.000 description 6
- 210000003016 hypothalamus Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 210000001428 peripheral nervous system Anatomy 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 229910052702 rhenium Inorganic materials 0.000 description 6
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 6
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 208000009935 visceral pain Diseases 0.000 description 6
- AADJJWDBCQRALD-UHFFFAOYSA-N (1-hydroxycyclohexyl)acetic acid Chemical compound OC(=O)CC1(O)CCCCC1 AADJJWDBCQRALD-UHFFFAOYSA-N 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 5
- BSWZNPSKWUUKRO-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)-2-naphthalen-2-ylacetic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(C(=O)O)C1(O)CCC1 BSWZNPSKWUUKRO-UHFFFAOYSA-N 0.000 description 5
- KYZJWANBOFKFGX-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-naphthalen-1-ylacetic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(=O)O)C1(O)CCCCC1 KYZJWANBOFKFGX-UHFFFAOYSA-N 0.000 description 5
- NFZQVADYFXRRPM-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OC(F)(F)F)=C1 NFZQVADYFXRRPM-UHFFFAOYSA-N 0.000 description 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 235000010290 biphenyl Nutrition 0.000 description 5
- 210000000133 brain stem Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001331 thermoregulatory effect Effects 0.000 description 5
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 4
- ZFUAOMZGERUFJP-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-(4-phenylmethoxyphenyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1OCC1=CC=CC=C1 ZFUAOMZGERUFJP-UHFFFAOYSA-N 0.000 description 4
- IDCUWIYVMAHUCC-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(4-hydroxy-1-methylpiperidin-4-yl)acetic acid Chemical compound C1CN(C)CCC1(O)C(C(O)=O)C1=CC=C(Cl)C(Cl)=C1 IDCUWIYVMAHUCC-UHFFFAOYSA-N 0.000 description 4
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 4
- VGVHNLRUAMRIEW-UHFFFAOYSA-N 4-methylcyclohexan-1-one Chemical compound CC1CCC(=O)CC1 VGVHNLRUAMRIEW-UHFFFAOYSA-N 0.000 description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 4
- 229940091886 4-tert-butylcyclohexanol Drugs 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 208000027520 Somatoform disease Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 150000001503 aryl iodides Chemical class 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- WUDZLJCFXIWBNC-UHFFFAOYSA-N cycloheptanol dihydrochloride Chemical compound Cl.Cl.C1(CCCCCC1)O WUDZLJCFXIWBNC-UHFFFAOYSA-N 0.000 description 4
- YKFKEYKJGVSEIX-UHFFFAOYSA-N cyclohexanone, 4-(1,1-dimethylethyl)- Chemical compound CC(C)(C)C1CCC(=O)CC1 YKFKEYKJGVSEIX-UHFFFAOYSA-N 0.000 description 4
- 125000004188 dichlorophenyl group Chemical group 0.000 description 4
- YSPVHAUJXLGZHP-UHFFFAOYSA-N ethyl piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCCCC1 YSPVHAUJXLGZHP-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 4
- DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 3
- BFIMGXLEZIYCTF-UHFFFAOYSA-N 1,2-dimethylpiperidin-4-amine;dihydrochloride Chemical compound Cl.Cl.CC1CC(N)CCN1C BFIMGXLEZIYCTF-UHFFFAOYSA-N 0.000 description 3
- PZQVDLYPNAADGQ-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CNCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 PZQVDLYPNAADGQ-UHFFFAOYSA-N 0.000 description 3
- ANBPNOYGZSBAGS-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.CCC1(O)CCCCC1 ANBPNOYGZSBAGS-UHFFFAOYSA-N 0.000 description 3
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 3
- OKIPAWMFSGGXNT-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-(4-phenoxyphenyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1OC1=CC=CC=C1 OKIPAWMFSGGXNT-UHFFFAOYSA-N 0.000 description 3
- PUYSGSMLPVGKOB-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(1-hydroxycyclobutyl)acetic acid Chemical compound C1CCC1(O)C(C(=O)O)C1=CC=C(Cl)C(Cl)=C1 PUYSGSMLPVGKOB-UHFFFAOYSA-N 0.000 description 3
- RFAVVUUOJOKONU-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1=C(Br)C(OC)=CC=C1C(C(O)=O)C1(O)CCCCC1 RFAVVUUOJOKONU-UHFFFAOYSA-N 0.000 description 3
- PBITZGRMRQYSTA-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-2-(4-tert-butyl-1-hydroxycyclohexyl)acetic acid Chemical compound C1=C(Br)C(OC)=CC=C1C(C(O)=O)C1(O)CCC(C(C)(C)C)CC1 PBITZGRMRQYSTA-UHFFFAOYSA-N 0.000 description 3
- POTVGQUUEQTPNA-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1Br POTVGQUUEQTPNA-UHFFFAOYSA-N 0.000 description 3
- SOTOBINBHNXAQK-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(4-hydroxy-1-methylpiperidin-4-yl)acetic acid Chemical compound C1CN(C)CCC1(O)C(C(O)=O)C1=CC=CC(Br)=C1 SOTOBINBHNXAQK-UHFFFAOYSA-N 0.000 description 3
- SEBRMRXJBDYXLW-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-cycloheptylacetic acid Chemical compound C=1C=CC(Cl)=CC=1C(C(=O)O)C1CCCCCC1 SEBRMRXJBDYXLW-UHFFFAOYSA-N 0.000 description 3
- DGISAMDVQQAGKN-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-cyclopentylacetic acid Chemical compound C=1C=CC(Cl)=CC=1C(C(=O)O)C1CCCC1 DGISAMDVQQAGKN-UHFFFAOYSA-N 0.000 description 3
- GJUOPPJLFZOCPM-UHFFFAOYSA-N 2-(4-bromophenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=C(Br)C=C1 GJUOPPJLFZOCPM-UHFFFAOYSA-N 0.000 description 3
- VARVNFDGRLLTCI-UHFFFAOYSA-N 2-(4-phenoxyphenyl)acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OC1=CC=CC=C1 VARVNFDGRLLTCI-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 description 3
- GMQDGVNZKIOYGP-UHFFFAOYSA-N 3-(3-chlorophenyl)-2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran-2-ol Chemical compound OC1OC2CCCCC2C1C1=CC=CC(Cl)=C1 GMQDGVNZKIOYGP-UHFFFAOYSA-N 0.000 description 3
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 3
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 3
- IIDAJRNSZSFFCB-UHFFFAOYSA-N 4-amino-5-methoxy-2-methylbenzenesulfonamide Chemical compound COC1=CC(S(N)(=O)=O)=C(C)C=C1N IIDAJRNSZSFFCB-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- 229910052691 Erbium Inorganic materials 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 241000009298 Trigla lyra Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000001543 aryl boronic acids Chemical class 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- MIHBFANPMPEZEI-UHFFFAOYSA-N benzonitrile dihydrochloride Chemical compound Cl.Cl.N#CC1=CC=CC=C1 MIHBFANPMPEZEI-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical group BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 3
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- GYUNDBTWSSGJJL-UHFFFAOYSA-N cyclooctanol dihydrochloride Chemical compound Cl.Cl.C1(CCCCCCC1)O GYUNDBTWSSGJJL-UHFFFAOYSA-N 0.000 description 3
- SNKYLLGDJMEMCT-UHFFFAOYSA-N cyclopentanol;dihydrochloride Chemical compound Cl.Cl.OC1CCCC1 SNKYLLGDJMEMCT-UHFFFAOYSA-N 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- WDWUXZRUATVGST-UHFFFAOYSA-N hexan-1-ol;hydrochloride Chemical compound Cl.CCCCCCO WDWUXZRUATVGST-UHFFFAOYSA-N 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- VXHFNALHLRWIIU-UHFFFAOYSA-N tert-butyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)C VXHFNALHLRWIIU-UHFFFAOYSA-N 0.000 description 3
- WUOQXNWMYLFAHT-QMMMGPOBSA-N tert-butyl n-[(3s)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCNC1 WUOQXNWMYLFAHT-QMMMGPOBSA-N 0.000 description 3
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 2
- IYTUKSIOQKTZEG-UHFFFAOYSA-N (3-chloro-4-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(Cl)=C1 IYTUKSIOQKTZEG-UHFFFAOYSA-N 0.000 description 2
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- SUTJIEOCDHUMGV-UHFFFAOYSA-N 1-(1-naphthalen-1-yl-2-piperazin-1-ylethyl)cycloheptan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CNCCN1CC(C=1C2=CC=CC=C2C=CC=1)C1(O)CCCCCC1 SUTJIEOCDHUMGV-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- MHAAJMKNAODMGC-UHFFFAOYSA-N 1-[1-(3-bromo-4-methoxyphenyl)-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1=C(Br)C(OC)=CC=C1C(C1(O)CCCCC1)CN1CCC(N2CCCC2)CC1 MHAAJMKNAODMGC-UHFFFAOYSA-N 0.000 description 2
- FZVIHDXTGCIHSF-UHFFFAOYSA-N 1-[1-(3-bromophenyl)-2-[[4-(trifluoromethyl)phenyl]methylamino]ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=C(C(F)(F)F)C=CC=1CNCC(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 FZVIHDXTGCIHSF-UHFFFAOYSA-N 0.000 description 2
- BXWBJEKTONZVNI-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-morpholin-4-ylethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C1COCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 BXWBJEKTONZVNI-UHFFFAOYSA-N 0.000 description 2
- RVYNLWCURWSQHX-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-(3,4-dichlorophenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC(C1(O)CCCCC1)C1=CC=C(Cl)C(Cl)=C1 RVYNLWCURWSQHX-UHFFFAOYSA-N 0.000 description 2
- AIGZXOUFYPSSKG-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]ethyl]cyclobutan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC(C1(O)CCC1)C1=CC=C(OC(F)(F)F)C=C1 AIGZXOUFYPSSKG-UHFFFAOYSA-N 0.000 description 2
- UDLCPUMQNDQXLS-UHFFFAOYSA-N 1-[2-(benzylamino)-1-(3-chlorophenyl)ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 UDLCPUMQNDQXLS-UHFFFAOYSA-N 0.000 description 2
- LGUABPURMQYARU-UHFFFAOYSA-N 1-[2-(benzylamino)-1-naphthalen-2-ylethyl]cyclobutan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCC1 LGUABPURMQYARU-UHFFFAOYSA-N 0.000 description 2
- DOBLDSCTPHFHBU-UHFFFAOYSA-N 1-[2-(benzylamino)-1-naphthalen-2-ylethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 DOBLDSCTPHFHBU-UHFFFAOYSA-N 0.000 description 2
- IQFOLKYJKYTXEV-MYULVRAQSA-N 1-[2-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1-naphthalen-1-ylethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](N(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=CC2=CC=CC=C12 IQFOLKYJKYTXEV-MYULVRAQSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- PTFYANCKQWXJJB-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)-1-morpholin-4-yl-2-naphthalen-2-ylethanone Chemical compound C1COCCN1C(=O)C(C=1C=C2C=CC=CC2=CC=1)C1(O)CCC1 PTFYANCKQWXJJB-UHFFFAOYSA-N 0.000 description 2
- CLSWWUPAPHCLKC-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)-2-naphthalen-1-ylacetic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(=O)O)C1(O)CCC1 CLSWWUPAPHCLKC-UHFFFAOYSA-N 0.000 description 2
- COAQGTHBRSXDHR-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-1-morpholin-4-yl-2-naphthalen-2-ylethanone Chemical compound C1COCCN1C(=O)C(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 COAQGTHBRSXDHR-UHFFFAOYSA-N 0.000 description 2
- DKTCQBZZJDHDOP-UHFFFAOYSA-N 2-(1-hydroxycyclopentyl)-2-naphthalen-1-ylacetic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(=O)O)C1(O)CCCC1 DKTCQBZZJDHDOP-UHFFFAOYSA-N 0.000 description 2
- WQFYLQPPAJZYES-UHFFFAOYSA-N 2-(2-bromophenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=CC=C1Br WQFYLQPPAJZYES-UHFFFAOYSA-N 0.000 description 2
- SMQRDDFVUOXNKL-UHFFFAOYSA-N 2-(2-chlorothiophen-3-yl)acetic acid Chemical compound OC(=O)CC=1C=CSC=1Cl SMQRDDFVUOXNKL-UHFFFAOYSA-N 0.000 description 2
- JXFNLVFNAXDMLR-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(4-hydroxy-1-methylpiperidin-4-yl)-1-morpholin-4-ylethanone Chemical compound C1CN(C)CCC1(O)C(C=1C=C(Cl)C(Cl)=CC=1)C(=O)N1CCOCC1 JXFNLVFNAXDMLR-UHFFFAOYSA-N 0.000 description 2
- ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 2
- ZATYMBKJXXBTLQ-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)acetic acid Chemical compound C1C(C)(C)CC(C)(C)CC1(O)C(C(O)=O)C1=CC=CC(Br)=C1 ZATYMBKJXXBTLQ-UHFFFAOYSA-N 0.000 description 2
- CISGWNAUANUCMQ-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxycyclobutyl)acetic acid Chemical compound C1CCC1(O)C(C(=O)O)C1=CC=CC(Br)=C1 CISGWNAUANUCMQ-UHFFFAOYSA-N 0.000 description 2
- YTNNGHQISXVQNP-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(2-hydroxy-2-adamantyl)acetic acid Chemical compound C1C2CC(C3)CC1CC3C2(O)C(C(=O)O)C1=CC=CC(Br)=C1 YTNNGHQISXVQNP-UHFFFAOYSA-N 0.000 description 2
- LSTDCYHSOJALQE-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(2-hydroxy-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl)acetic acid Chemical compound OC1CCC2CCCCC2C1C(C(O)=O)C1=CC=CC(Cl)=C1 LSTDCYHSOJALQE-UHFFFAOYSA-N 0.000 description 2
- FIXZHBSMHVBSRE-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(2-hydroxycyclohexyl)acetic acid Chemical compound OC1CCCCC1C(C(O)=O)C1=CC=CC(Cl)=C1 FIXZHBSMHVBSRE-UHFFFAOYSA-N 0.000 description 2
- YAKDHCLWOYVISZ-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-cyclohexylacetic acid Chemical compound C=1C=CC(Cl)=CC=1C(C(=O)O)C1CCCCC1 YAKDHCLWOYVISZ-UHFFFAOYSA-N 0.000 description 2
- ZWBRBLMKOBHGIH-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-hydroxy-3-methylbutanoic acid Chemical compound CC(C)(O)C(C(O)=O)C1=CC=CC(Cl)=C1 ZWBRBLMKOBHGIH-UHFFFAOYSA-N 0.000 description 2
- ZIWFTYFBXXNURI-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-hydroxy-3-propylhexanoic acid Chemical compound CCCC(O)(CCC)C(C(O)=O)C1=CC=CC(Cl)=C1 ZIWFTYFBXXNURI-UHFFFAOYSA-N 0.000 description 2
- WQYBIHZSMNVHNP-UHFFFAOYSA-N 2-(3-fluoro-4-phenylmethoxyphenyl)acetic acid Chemical compound FC1=CC(CC(=O)O)=CC=C1OCC1=CC=CC=C1 WQYBIHZSMNVHNP-UHFFFAOYSA-N 0.000 description 2
- LLZKAZNUCYYBQO-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(OCC=2C=CC=CC=2)=C1 LLZKAZNUCYYBQO-UHFFFAOYSA-N 0.000 description 2
- OUAYRHHVBAKDLD-UHFFFAOYSA-N 2-(4-bromophenyl)-2-(1-hydroxycyclobutyl)acetic acid Chemical compound C1CCC1(O)C(C(=O)O)C1=CC=C(Br)C=C1 OUAYRHHVBAKDLD-UHFFFAOYSA-N 0.000 description 2
- YSDSMUFVXGKDCY-UHFFFAOYSA-N 2-(4-ethyl-1-hydroxycyclohexyl)-2-naphthalen-1-ylacetic acid Chemical compound C1CC(CC)CCC1(O)C(C(O)=O)C1=CC=CC2=CC=CC=C12 YSDSMUFVXGKDCY-UHFFFAOYSA-N 0.000 description 2
- TZALSBVNCZGXFV-UHFFFAOYSA-N 2-(4-tert-butyl-1-hydroxycyclohexyl)-2-(3-chlorophenyl)acetic acid Chemical compound C1CC(C(C)(C)C)CCC1(O)C(C(O)=O)C1=CC=CC(Cl)=C1 TZALSBVNCZGXFV-UHFFFAOYSA-N 0.000 description 2
- ZOORJRWBFJPSIL-UHFFFAOYSA-N 2-(5-bromothiophen-2-yl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=C(Br)S1 ZOORJRWBFJPSIL-UHFFFAOYSA-N 0.000 description 2
- SOSRMLNIYLBVKL-UHFFFAOYSA-N 2-(5-chlorothiophen-2-yl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=C(Cl)S1 SOSRMLNIYLBVKL-UHFFFAOYSA-N 0.000 description 2
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 2
- BLXXCCIBGGBDHI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1 BLXXCCIBGGBDHI-UHFFFAOYSA-N 0.000 description 2
- CJPLUOQUJMWWNV-UHFFFAOYSA-N 2-[3-chloro-4-[(2-methoxyphenyl)methoxy]phenyl]acetic acid Chemical compound COC1=CC=CC=C1COC1=CC=C(CC(O)=O)C=C1Cl CJPLUOQUJMWWNV-UHFFFAOYSA-N 0.000 description 2
- GDYHGKKOVBCIBK-UHFFFAOYSA-N 2-[4-(cyclohexylmethoxy)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCC1CCCCC1 GDYHGKKOVBCIBK-UHFFFAOYSA-N 0.000 description 2
- ZMTIBXQPXBUWPQ-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(OC(F)(F)F)C=C1 ZMTIBXQPXBUWPQ-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical group OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- OQJMHUOCLRCSED-UHFFFAOYSA-N 3,3,5,5-tetramethylcyclohexan-1-one Chemical compound CC1(C)CC(=O)CC(C)(C)C1 OQJMHUOCLRCSED-UHFFFAOYSA-N 0.000 description 2
- LGVJRKCQQHOWAU-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-1h-naphthalen-2-one Chemical compound C1CCCC2CC(=O)CCC21 LGVJRKCQQHOWAU-UHFFFAOYSA-N 0.000 description 2
- GVSJDNVWWDUZCV-UHFFFAOYSA-N 3-(2,2-dibromoethenyl)quinoline Chemical compound C1=CC=CC2=CC(C=C(Br)Br)=CN=C21 GVSJDNVWWDUZCV-UHFFFAOYSA-N 0.000 description 2
- UOTMHAOCAJROQF-UHFFFAOYSA-N 3-bromo-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Br UOTMHAOCAJROQF-UHFFFAOYSA-N 0.000 description 2
- NIJQTMGYGHKABJ-UHFFFAOYSA-N 4-(2,2-dibromoethenyl)-1-phenylmethoxy-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC(C=C(Br)Br)=CC=C1OCC1=CC=CC=C1 NIJQTMGYGHKABJ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- GPJSLRQIOKFRFL-UHFFFAOYSA-N 4-hydroxy-3-(trifluoromethoxy)benzaldehyde Chemical compound OC1=CC=C(C=O)C=C1OC(F)(F)F GPJSLRQIOKFRFL-UHFFFAOYSA-N 0.000 description 2
- OARCFVUPNVMSFF-UHFFFAOYSA-N 4-phenylmethoxy-3-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 OARCFVUPNVMSFF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- OMUDERJOHBOFLD-UHFFFAOYSA-N C(C)(C)(C)C(=O)O.N1CCNCC1 Chemical compound C(C)(C)(C)C(=O)O.N1CCNCC1 OMUDERJOHBOFLD-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010064012 Central pain syndrome Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- ZLDDIXQOBPTXIZ-UHFFFAOYSA-N Cl.Cl.CC1CCN(CC1)CC(C1=CC=CC2=CC=CC=C12)C1(CCCCCCC1)O Chemical compound Cl.Cl.CC1CCN(CC1)CC(C1=CC=CC2=CC=CC=C12)C1(CCCCCCC1)O ZLDDIXQOBPTXIZ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000029061 Temperature regulation disease Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- UWDFWVLAHRQSKK-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OC(F)(F)F)=C1 UWDFWVLAHRQSKK-UHFFFAOYSA-N 0.000 description 2
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical group CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 125000004802 cyanophenyl group Chemical group 0.000 description 2
- 239000009937 cyclo 3 Substances 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000005567 fluorenylene group Chemical group 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MQWCXKGKQLNYQG-UHFFFAOYSA-N methyl cyclohexan-4-ol Natural products CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- MHGGNPLGBJPLLN-UHFFFAOYSA-N piperidine-1,2,2-tricarboxylic acid Chemical compound N1(C(CCCC1)(C(=O)O)C(=O)O)C(=O)O MHGGNPLGBJPLLN-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- QWJFBNRPVIHFSQ-UHFFFAOYSA-N propan-1-ol;dihydrochloride Chemical compound Cl.Cl.CCCO QWJFBNRPVIHFSQ-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- KCQJLTOSSVXOCC-UHFFFAOYSA-N tributyl(prop-1-ynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC KCQJLTOSSVXOCC-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
- 229960000317 yohimbine Drugs 0.000 description 2
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- NNTFPBXQPOQRBT-UHFFFAOYSA-N (2,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC=C1Cl NNTFPBXQPOQRBT-UHFFFAOYSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- IFNWESYYDINUHV-OLQVQODUSA-N (2s,6r)-2,6-dimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1 IFNWESYYDINUHV-OLQVQODUSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- DKYRKAIKWFHQHM-UHFFFAOYSA-N (3,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(Cl)=C1 DKYRKAIKWFHQHM-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- HTNVFUBCWIYPJN-HSZRJFAPSA-N (3r)-3,5-dimethyl-3-(4-methylpent-3-enyl)-11h-pyrano[3,2-a]carbazole Chemical compound C1=CC=C2C3=CC(C)=C4O[C@@](CCC=C(C)C)(C)C=CC4=C3NC2=C1 HTNVFUBCWIYPJN-HSZRJFAPSA-N 0.000 description 1
- AOKRXIIIYJGNNU-RXMQYKEDSA-N (3r)-3-methylcyclopentan-1-one Chemical compound C[C@@H]1CCC(=O)C1 AOKRXIIIYJGNNU-RXMQYKEDSA-N 0.000 description 1
- WRTCOTWKXLHMJW-UHFFFAOYSA-N (4-hydroxyphenyl)methyl acetate Chemical compound CC(=O)OCC1=CC=C(O)C=C1 WRTCOTWKXLHMJW-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- FEOMFFKZOZMBKD-UHFFFAOYSA-N (4-phenoxyphenyl)methanol Chemical compound C1=CC(CO)=CC=C1OC1=CC=CC=C1 FEOMFFKZOZMBKD-UHFFFAOYSA-N 0.000 description 1
- PHJFLPMVEFKEPL-UHFFFAOYSA-N (6-methoxy-2-naphthyl)acetic acid Chemical compound C1=C(CC(O)=O)C=CC2=CC(OC)=CC=C21 PHJFLPMVEFKEPL-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IJLOKQVNRAVDJE-BTJKTKAUSA-N (z)-but-2-enedioic acid;cyclohexanol Chemical compound OC1CCCCC1.OC(=O)\C=C/C(O)=O IJLOKQVNRAVDJE-BTJKTKAUSA-N 0.000 description 1
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- CMHPUBKZZPSUIQ-UHFFFAOYSA-N 1,3-benzodioxol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCOC2=C1 CMHPUBKZZPSUIQ-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical group C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- FLRUNCJXOVYWDH-UHFFFAOYSA-N 1-(2-bromoethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCBr)C=C1 FLRUNCJXOVYWDH-UHFFFAOYSA-N 0.000 description 1
- GPHCPUFIWQJZOI-UHFFFAOYSA-N 1-(2-bromoethyl)naphthalene Chemical compound C1=CC=C2C(CCBr)=CC=CC2=C1 GPHCPUFIWQJZOI-UHFFFAOYSA-N 0.000 description 1
- ACNISRGLLUHIDN-UHFFFAOYSA-N 1-(2-morpholin-4-yl-1-naphthalen-2-ylethyl)cyclobutan-1-ol;hydrochloride Chemical compound Cl.C1COCCN1CC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCC1 ACNISRGLLUHIDN-UHFFFAOYSA-N 0.000 description 1
- LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
- IPGKUSAAWUPSFG-UHFFFAOYSA-N 1-(2-piperazin-1-yl-1-quinolin-3-ylethyl)cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CNCCN1CC(C=1C=C2C=CC=CC2=NC=1)C1(O)CCCCC1 IPGKUSAAWUPSFG-UHFFFAOYSA-N 0.000 description 1
- VGISFWWEOGVMED-UHFFFAOYSA-N 1-(chloromethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CCl)=C1 VGISFWWEOGVMED-UHFFFAOYSA-N 0.000 description 1
- SGRQUYSYZPMAPU-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2,2-dicarboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCCC1(C(O)=O)C(O)=O SGRQUYSYZPMAPU-UHFFFAOYSA-N 0.000 description 1
- MXDJTZKBLFUFPI-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)-2-[4-(methylamino)piperidin-1-yl]ethyl]cyclohexan-1-ol Chemical compound C1CC(NC)CCN1CC(C1(O)CCCCC1)C1=CC=C(Cl)C(Cl)=C1 MXDJTZKBLFUFPI-UHFFFAOYSA-N 0.000 description 1
- PPVIWCCBXKMCER-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)-2-[4-(methylamino)piperidin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(NC)CCN1CC(C1(O)CCCCC1)C1=CC=C(Cl)C(Cl)=C1 PPVIWCCBXKMCER-UHFFFAOYSA-N 0.000 description 1
- NEPQDOCTZNUGQH-UHFFFAOYSA-N 1-[1-(3,4-dichlorophenyl)-2-morpholin-4-ylethyl]cyclobutan-1-ol;hydrochloride Chemical compound Cl.C1COCCN1CC(C=1C=C(Cl)C(Cl)=CC=1)C1(O)CCC1 NEPQDOCTZNUGQH-UHFFFAOYSA-N 0.000 description 1
- QQMFGZVXHOYHFF-UHFFFAOYSA-N 1-[1-(3-bromophenyl)-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N2CCCC2)CCN1CC(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 QQMFGZVXHOYHFF-UHFFFAOYSA-N 0.000 description 1
- CBKUEJQKYWWJIR-UHFFFAOYSA-N 1-[1-(3-bromophenyl)-2-(cyclohexylamino)ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C1CCCCC1NCC(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 CBKUEJQKYWWJIR-UHFFFAOYSA-N 0.000 description 1
- JHTLRJIFHDNEFA-UHFFFAOYSA-N 1-[1-(3-bromophenyl)-2-morpholin-4-ylethyl]cyclobutan-1-ol;hydrochloride Chemical compound Cl.C1COCCN1CC(C=1C=C(Br)C=CC=1)C1(O)CCC1 JHTLRJIFHDNEFA-UHFFFAOYSA-N 0.000 description 1
- ZGJKAFRMONTUAK-ALSOZGBCSA-N 1-[1-(3-chloro-4-phenylmethoxyphenyl)-2-[(3s)-3-(dimethylamino)piperidin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](N(C)C)CCCN1CC(C1(O)CCCCC1)C(C=C1Cl)=CC=C1OCC1=CC=CC=C1 ZGJKAFRMONTUAK-ALSOZGBCSA-N 0.000 description 1
- KORRHYJQPWWYEA-DRYXINTFSA-N 1-[1-(3-chloro-4-phenylmethoxyphenyl)-2-[(3s)-3-(methylamino)pyrrolidin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](NC)CCN1CC(C1(O)CCCCC1)C(C=C1Cl)=CC=C1OCC1=CC=CC=C1 KORRHYJQPWWYEA-DRYXINTFSA-N 0.000 description 1
- ZPBKQBHZQNKRIU-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(4-piperidin-1-ylpiperidin-1-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N2CCCCC2)CCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 ZPBKQBHZQNKRIU-UHFFFAOYSA-N 0.000 description 1
- IHVWEKYKMLMEDS-SEFHDJSNSA-N 1-[1-(3-chlorophenyl)-2-[(3s)-3-(methylamino)pyrrolidin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](NC)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 IHVWEKYKMLMEDS-SEFHDJSNSA-N 0.000 description 1
- BPVHAXIVYGFKOY-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-(3-phenylbutyl)piperazin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=CC=1C(C)CCN(CC1)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 BPVHAXIVYGFKOY-UHFFFAOYSA-N 0.000 description 1
- XKOCQKZDILHUDH-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-(dimethylamino)piperidin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 XKOCQKZDILHUDH-UHFFFAOYSA-N 0.000 description 1
- LISNBFOTEKGYIL-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-(pyridin-3-ylmethyl)piperazin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CN(CC=2C=NC=CC=2)CCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 LISNBFOTEKGYIL-UHFFFAOYSA-N 0.000 description 1
- WEHUJILWYXAIEO-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-[(5-ethylfuran-2-yl)methyl]piperazin-1-yl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.O1C(CC)=CC=C1CN1CCN(CC(C=2C=C(Cl)C=CC=2)C2(O)CCCCC2)CC1 WEHUJILWYXAIEO-UHFFFAOYSA-N 0.000 description 1
- KBBBLIXJWWMMCO-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]-3,4,4a,5,6,7,8,8a-octahydro-2h-naphthalen-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CCC2CCCCC2C1(O)C(C=1C=C(Cl)C=CC=1)CN1CCNCC1 KBBBLIXJWWMMCO-UHFFFAOYSA-N 0.000 description 1
- XRPFDANMJKPZLW-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperidin-1-ylethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C1CCCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 XRPFDANMJKPZLW-UHFFFAOYSA-N 0.000 description 1
- MOVFDALBQXQPCO-UHFFFAOYSA-N 1-[1-(6-methoxynaphthalen-2-yl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C1(O)CCCCC1)CN1CCN(C)CC1 MOVFDALBQXQPCO-UHFFFAOYSA-N 0.000 description 1
- PRHJTLWEXLWKKY-UHFFFAOYSA-N 1-[1-[3-(3,4-dimethoxyphenyl)phenyl]-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=CC(C(CN2CCNCC2)C2(O)CCCCC2)=C1 PRHJTLWEXLWKKY-UHFFFAOYSA-N 0.000 description 1
- SFRUDVVIRONFKI-UHFFFAOYSA-N 1-[1-[3-(4-chlorophenyl)phenyl]-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CNCCN1CC(C=1C=C(C=CC=1)C=1C=CC(Cl)=CC=1)C1(O)CCCCC1 SFRUDVVIRONFKI-UHFFFAOYSA-N 0.000 description 1
- BANAVMQZRYRDSK-UHFFFAOYSA-N 1-[1-[4-(2-chlorophenyl)phenyl]-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CNCCN1CC(C=1C=CC(=CC=1)C=1C(=CC=CC=1)Cl)C1(O)CCCCC1 BANAVMQZRYRDSK-UHFFFAOYSA-N 0.000 description 1
- XGWLFIBOYUJCLP-UHFFFAOYSA-N 1-[1-[4-(3,4-dichlorophenyl)phenyl]-2-piperazin-1-ylethyl]cyclobutan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CNCCN1CC(C=1C=CC(=CC=1)C=1C=C(Cl)C(Cl)=CC=1)C1(O)CCC1 XGWLFIBOYUJCLP-UHFFFAOYSA-N 0.000 description 1
- CWDDOYNJPSEQHR-UHFFFAOYSA-N 1-[1-naphthalen-2-yl-2-(4-piperidin-1-ylpiperidin-1-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N2CCCCC2)CCN1CC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 CWDDOYNJPSEQHR-UHFFFAOYSA-N 0.000 description 1
- MGSUTQBUGDWZKK-UHFFFAOYSA-N 1-[1-naphthalen-2-yl-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N2CCCC2)CCN1CC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 MGSUTQBUGDWZKK-UHFFFAOYSA-N 0.000 description 1
- YVGNLAZYCJZZBX-UHFFFAOYSA-N 1-[2-(3-chlorophenyl)-2-cyclopentylethyl]-4-methylpiperazine;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CC(C=1C=C(Cl)C=CC=1)C1CCCC1 YVGNLAZYCJZZBX-UHFFFAOYSA-N 0.000 description 1
- RPJQLMHJJQCYMG-UHFFFAOYSA-N 1-[2-(3-chlorophenyl)-2-cyclopentylethyl]piperazine;dihydrochloride Chemical compound Cl.Cl.ClC1=CC=CC(C(CN2CCNCC2)C2CCCC2)=C1 RPJQLMHJJQCYMG-UHFFFAOYSA-N 0.000 description 1
- HVQWIUXGTPPNJI-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-(3-bromo-4-methoxyphenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1=C(Br)C(OC)=CC=C1C(C1(O)CCCCC1)CN1CCC(N)CC1 HVQWIUXGTPPNJI-UHFFFAOYSA-N 0.000 description 1
- PDXNGYPVZCQINW-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-(3-chlorophenyl)ethyl]cyclohexan-1-ol Chemical compound C1CC(N)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 PDXNGYPVZCQINW-UHFFFAOYSA-N 0.000 description 1
- IUZBQSNNSLGLAR-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-(5-chlorothiophen-3-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC(C1(O)CCCCC1)C1=CSC(Cl)=C1 IUZBQSNNSLGLAR-UHFFFAOYSA-N 0.000 description 1
- LTGDKKXOMQJMIU-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-(5-methoxy-1-benzothiophen-3-yl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=CC=C2SC=C1C(C1(O)CCCCC1)CN1CCC(N)CC1 LTGDKKXOMQJMIU-UHFFFAOYSA-N 0.000 description 1
- SFOWKBVDHIQPIY-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-[4-(trifluoromethoxy)phenyl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC(C1(O)CCCCC1)C1=CC=C(OC(F)(F)F)C=C1 SFOWKBVDHIQPIY-UHFFFAOYSA-N 0.000 description 1
- VEALBBNLMSGRDL-UHFFFAOYSA-N 1-[2-(4-aminopiperidin-1-yl)-1-naphthalen-1-ylethyl]cyclobutan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC(C1(O)CCC1)C1=CC=CC2=CC=CC=C12 VEALBBNLMSGRDL-UHFFFAOYSA-N 0.000 description 1
- RQJFCCCKAMKUKV-UHFFFAOYSA-N 1-[2-(4-methylpiperazin-1-yl)-1-(4-phenoxyphenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CC(C1(O)CCCCC1)C(C=C1)=CC=C1OC1=CC=CC=C1 RQJFCCCKAMKUKV-UHFFFAOYSA-N 0.000 description 1
- YYJIBHFMUZUGND-UHFFFAOYSA-N 1-[2-(4-methylpiperazin-1-yl)-1-[4-(trifluoromethoxy)phenyl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=C(OC(F)(F)F)C=C1 YYJIBHFMUZUGND-UHFFFAOYSA-N 0.000 description 1
- NAKNQHNRCTUEDV-UHFFFAOYSA-N 1-[2-(4-piperidin-1-ylpiperidin-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CC(N2CCCCC2)CCN1CC(C=1C=C(C=CC=1)C(F)(F)F)C1(O)CCCCC1 NAKNQHNRCTUEDV-UHFFFAOYSA-N 0.000 description 1
- AANYYRCJLCRSAF-UHFFFAOYSA-N 1-[2-(4-piperidin-1-ylpiperidin-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(N2CCCCC2)CCN1CC(C=1C=C(C=CC=1)C(F)(F)F)C1(O)CCCCC1 AANYYRCJLCRSAF-UHFFFAOYSA-N 0.000 description 1
- DDQFAUZSTFKNPW-UHFFFAOYSA-N 1-[2-(benzylamino)-1-(3,4-dichlorophenyl)ethyl]cyclobutan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C(Cl)C(Cl)=CC=1)C1(O)CCC1 DDQFAUZSTFKNPW-UHFFFAOYSA-N 0.000 description 1
- ZDYLWPNVZJJWHP-UHFFFAOYSA-N 1-[2-(benzylamino)-1-(3,4-dichlorophenyl)ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C(Cl)C(Cl)=CC=1)C1(O)CCCCC1 ZDYLWPNVZJJWHP-UHFFFAOYSA-N 0.000 description 1
- NAKCKHQGGLIYFH-UHFFFAOYSA-N 1-[2-(benzylamino)-1-(3-bromophenyl)ethyl]cyclobutan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C(Br)C=CC=1)C1(O)CCC1 NAKCKHQGGLIYFH-UHFFFAOYSA-N 0.000 description 1
- APAVPNXDQLKTOD-UHFFFAOYSA-N 1-[2-(benzylamino)-1-(3-bromophenyl)ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CNCC(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 APAVPNXDQLKTOD-UHFFFAOYSA-N 0.000 description 1
- BRBDOHFZYATBNK-LXTUAOQPSA-N 1-[2-[(3s)-3-(methylamino)pyrrolidin-1-yl]-1-(4-phenylmethoxyphenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](NC)CCN1CC(C1(O)CCCCC1)C(C=C1)=CC=C1OCC1=CC=CC=C1 BRBDOHFZYATBNK-LXTUAOQPSA-N 0.000 description 1
- DVHUSLPVEFQUIF-VEEDUFMYSA-N 1-[2-[(3s)-3-aminopyrrolidin-1-yl]-1-(3-chlorophenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](N)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 DVHUSLPVEFQUIF-VEEDUFMYSA-N 0.000 description 1
- LVPCQZDSRUUFOO-UHFFFAOYSA-N 1-[2-[(4-fluorophenyl)methylamino]-1-naphthalen-2-ylethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C=1C=C(F)C=CC=1CNCC(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 LVPCQZDSRUUFOO-UHFFFAOYSA-N 0.000 description 1
- IAFXHRKVXPTGNQ-UHFFFAOYSA-N 1-[2-[4-(methylamino)piperidin-1-yl]-1-naphthalen-2-ylethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CC(NC)CCN1CC(C1(O)CCCCC1)C1=CC=C(C=CC=C2)C2=C1 IAFXHRKVXPTGNQ-UHFFFAOYSA-N 0.000 description 1
- XFBVHRKLWFEXDI-UHFFFAOYSA-N 1-[2-piperazin-1-yl-1-(3-prop-1-ynylphenyl)ethyl]cyclohexan-1-ol Chemical compound CC#CC1=CC=CC(C(CN2CCNCC2)C2(O)CCCCC2)=C1 XFBVHRKLWFEXDI-UHFFFAOYSA-N 0.000 description 1
- PRDNJZHVBFERHV-UHFFFAOYSA-N 1-[2-piperazin-1-yl-1-(4-prop-1-ynylphenyl)ethyl]cyclohexan-1-ol Chemical compound C1=CC(C#CC)=CC=C1C(C1(O)CCCCC1)CN1CCNCC1 PRDNJZHVBFERHV-UHFFFAOYSA-N 0.000 description 1
- GMLRHYKFFMDFBK-UHFFFAOYSA-N 1-[2-piperazin-1-yl-1-(4-thiophen-3-ylphenyl)ethyl]cyclohexan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CNCCN1CC(C=1C=CC(=CC=1)C1=CSC=C1)C1(O)CCCCC1 GMLRHYKFFMDFBK-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 1
- RCHLXMOXBJRGNX-UHFFFAOYSA-N 1-butylcyclohexan-1-ol Chemical compound CCCCC1(O)CCCCC1 RCHLXMOXBJRGNX-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- REXGGJAEJCDHDD-UHFFFAOYSA-N 1-methoxypiperidine Chemical compound CON1CCCCC1 REXGGJAEJCDHDD-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- FTGZMZBYOHMEPS-UHFFFAOYSA-N 2,2-dimethylcyclopentan-1-one Chemical compound CC1(C)CCCC1=O FTGZMZBYOHMEPS-UHFFFAOYSA-N 0.000 description 1
- FGYBDASKYMSNCX-UHFFFAOYSA-N 2,5-dichlorothiophene Chemical compound ClC1=CC=C(Cl)S1 FGYBDASKYMSNCX-UHFFFAOYSA-N 0.000 description 1
- XOEFFNKFVAVPNH-UHFFFAOYSA-N 2-(1-hydroxy-2,2-dimethylcyclopentyl)-2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound CC1(C)CCCC1(O)C(C(O)=O)C1=CC=CC(OC(F)(F)F)=C1 XOEFFNKFVAVPNH-UHFFFAOYSA-N 0.000 description 1
- OZQCUHIJAKBMOM-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)-2-(3-phenylmethoxyphenyl)acetic acid Chemical compound C1CCC1(O)C(C(=O)O)C(C=1)=CC=CC=1OCC1=CC=CC=C1 OZQCUHIJAKBMOM-UHFFFAOYSA-N 0.000 description 1
- MHQZCKXYAMHQOV-UHFFFAOYSA-N 2-(1-hydroxycyclobutyl)-2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound C1CCC1(O)C(C(=O)O)C1=CC=CC(OC(F)(F)F)=C1 MHQZCKXYAMHQOV-UHFFFAOYSA-N 0.000 description 1
- BUWXYMMPKVJGKZ-UHFFFAOYSA-N 2-(1-hydroxycycloheptyl)acetic acid Chemical compound OC(=O)CC1(O)CCCCCC1 BUWXYMMPKVJGKZ-UHFFFAOYSA-N 0.000 description 1
- HNHXQYVVNOWFAC-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-1-(4-piperidin-1-ylpiperidin-1-yl)-2-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound C1CC(N2CCCCC2)CCN1C(=O)C(C=1C=CC(OC(F)(F)F)=CC=1)C1(O)CCCCC1 HNHXQYVVNOWFAC-UHFFFAOYSA-N 0.000 description 1
- XCMZWIWXKCADCK-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-1-(4-pyrrolidin-1-ylpiperidin-1-yl)-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1CC(N2CCCC2)CCN1C(=O)C(C=1C=C(C=CC=1)C(F)(F)F)C1(O)CCCCC1 XCMZWIWXKCADCK-UHFFFAOYSA-N 0.000 description 1
- YGVKMLDTGQRFQD-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-(3-methoxy-4-phenylmethoxyphenyl)acetic acid Chemical compound COC1=CC(C(C(O)=O)C2(O)CCCCC2)=CC=C1OCC1=CC=CC=C1 YGVKMLDTGQRFQD-UHFFFAOYSA-N 0.000 description 1
- DXUKMIGXXVNEJB-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-(3-phenoxyphenyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=1)=CC=CC=1OC1=CC=CC=C1 DXUKMIGXXVNEJB-UHFFFAOYSA-N 0.000 description 1
- XCUHDABATMOHLA-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-(6-methoxynaphthalen-2-yl)acetic acid Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C(O)=O)C1(O)CCCCC1 XCUHDABATMOHLA-UHFFFAOYSA-N 0.000 description 1
- BVPZEAPZDRHHQA-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[4-(2-naphthalen-1-ylethoxy)phenyl]acetic acid Chemical compound C=1C=C(OCCC=2C3=CC=CC=C3C=CC=2)C=CC=1C(C(=O)O)C1(O)CCCCC1 BVPZEAPZDRHHQA-UHFFFAOYSA-N 0.000 description 1
- WGIVDTBPPGZWOC-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[4-(2-phenylethoxy)phenyl]acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1OCCC1=CC=CC=C1 WGIVDTBPPGZWOC-UHFFFAOYSA-N 0.000 description 1
- VQFCGTMPBSTTCK-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-[4-(2-phenylethyl)phenyl]acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1CCC1=CC=CC=C1 VQFCGTMPBSTTCK-UHFFFAOYSA-N 0.000 description 1
- BHLLHJMJPDVAIB-UHFFFAOYSA-N 2-(1-hydroxycyclohexyl)-2-naphthalen-2-yl-1-(4-piperidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1CC(N2CCCCC2)CCN1C(=O)C(C=1C=C2C=CC=CC2=CC=1)C1(O)CCCCC1 BHLLHJMJPDVAIB-UHFFFAOYSA-N 0.000 description 1
- WKDBWZBIQUATNI-UHFFFAOYSA-N 2-(1-hydroxycyclooctyl)-2-naphthalen-1-ylacetic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(=O)O)C1(O)CCCCCCC1 WKDBWZBIQUATNI-UHFFFAOYSA-N 0.000 description 1
- BWJJFJQSWCMTSL-UHFFFAOYSA-N 2-(1-hydroxycyclooctyl)acetic acid Chemical compound OC(=O)CC1(O)CCCCCCC1 BWJJFJQSWCMTSL-UHFFFAOYSA-N 0.000 description 1
- LTBPRPATSZONGJ-UHFFFAOYSA-N 2-(1-methylcyclohexyl)acetic acid Chemical compound OC(=O)CC1(C)CCCCC1 LTBPRPATSZONGJ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JMZXUBICVRRNPV-UHFFFAOYSA-N 2-(2,5-dichlorothiophen-3-yl)acetic acid Chemical compound OC(=O)CC=1C=C(Cl)SC=1Cl JMZXUBICVRRNPV-UHFFFAOYSA-N 0.000 description 1
- DWXSYDKEWORWBT-UHFFFAOYSA-N 2-(2-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-N 0.000 description 1
- JJHMUUSRNNYWQR-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(1-hydroxycyclohexyl)-1-(4-pyrrolidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1CC(N2CCCC2)CCN1C(=O)C(C=1C=C(Cl)C(Cl)=CC=1)C1(O)CCCCC1 JJHMUUSRNNYWQR-UHFFFAOYSA-N 0.000 description 1
- SKARCIAFKUSVEF-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C1=CC=C(Cl)C(Cl)=C1 SKARCIAFKUSVEF-UHFFFAOYSA-N 0.000 description 1
- MVCKYMNDRAZOFB-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-2-(1-hydroxycyclohexyl)-1-(4-pyrrolidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1=C(Br)C(OC)=CC=C1C(C1(O)CCCCC1)C(=O)N1CCC(N2CCCC2)CC1 MVCKYMNDRAZOFB-UHFFFAOYSA-N 0.000 description 1
- UGLMXXJDSSGNBH-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-3-ethyl-3-hydroxypentanoic acid Chemical compound CCC(O)(CC)C(C(O)=O)C1=CC=C(OC)C(Br)=C1 UGLMXXJDSSGNBH-UHFFFAOYSA-N 0.000 description 1
- AAXQAXLJDIWEDA-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxycyclobutyl)-1-morpholin-4-ylethanone Chemical compound C1COCCN1C(=O)C(C=1C=C(Br)C=CC=1)C1(O)CCC1 AAXQAXLJDIWEDA-UHFFFAOYSA-N 0.000 description 1
- QSFCAMWVKWKWJJ-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxycyclohexyl)-1-(4-piperidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1CC(N2CCCCC2)CCN1C(=O)C(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 QSFCAMWVKWKWJJ-UHFFFAOYSA-N 0.000 description 1
- LMZWXBMHHRWZEI-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(1-hydroxycyclohexyl)-1-morpholin-4-ylethanone Chemical compound C1COCCN1C(=O)C(C=1C=C(Br)C=CC=1)C1(O)CCCCC1 LMZWXBMHHRWZEI-UHFFFAOYSA-N 0.000 description 1
- ASHOAJPLSWDRAV-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(4-hydroxy-1-methylpiperidin-4-yl)-1-morpholin-4-ylethanone Chemical compound C1CN(C)CCC1(O)C(C=1C=C(Br)C=CC=1)C(=O)N1CCOCC1 ASHOAJPLSWDRAV-UHFFFAOYSA-N 0.000 description 1
- VOIOODAAHKITML-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(4-tert-butyl-1-hydroxycyclohexyl)acetic acid Chemical compound C1CC(C(C)(C)C)CCC1(O)C(C(O)=O)C1=CC=CC(Br)=C1 VOIOODAAHKITML-UHFFFAOYSA-N 0.000 description 1
- OYNMABZTYHDWRJ-UHFFFAOYSA-N 2-(3-bromophenyl)-3-ethyl-3-hydroxypentanoic acid Chemical compound CCC(O)(CC)C(C(O)=O)C1=CC=CC(Br)=C1 OYNMABZTYHDWRJ-UHFFFAOYSA-N 0.000 description 1
- SBPIMNAIXFBQRD-UHFFFAOYSA-N 2-(3-bromophenyl)-3-hydroxy-3-propylhexanoic acid Chemical compound CCCC(O)(CCC)C(C(O)=O)C1=CC=CC(Br)=C1 SBPIMNAIXFBQRD-UHFFFAOYSA-N 0.000 description 1
- HOWVDBDGGWZFRY-UHFFFAOYSA-N 2-(3-chloro-4-phenylmethoxyphenyl)-2-(1-hydroxycyclohexyl)-1-(4-methoxypiperidin-1-yl)ethanone Chemical compound C1CC(OC)CCN1C(=O)C(C1(O)CCCCC1)C(C=C1Cl)=CC=C1OCC1=CC=CC=C1 HOWVDBDGGWZFRY-UHFFFAOYSA-N 0.000 description 1
- DFHBBMJTBBLQSA-UHFFFAOYSA-N 2-(3-chloro-4-phenylmethoxyphenyl)acetic acid Chemical compound ClC1=CC(CC(=O)O)=CC=C1OCC1=CC=CC=C1 DFHBBMJTBBLQSA-UHFFFAOYSA-N 0.000 description 1
- MUEQTUWIQMPYSE-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxy-3,3,5,5-tetramethylcyclohexyl)acetic acid Chemical compound C1C(C)(C)CC(C)(C)CC1(O)C(C(O)=O)C1=CC=CC(Cl)=C1 MUEQTUWIQMPYSE-UHFFFAOYSA-N 0.000 description 1
- LRKOXEUNEVGZCA-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxy-3,4,4a,5,6,7,8,8a-octahydro-2h-naphthalen-1-yl)acetic acid Chemical compound C1CCC2CCCCC2C1(O)C(C(=O)O)C1=CC=CC(Cl)=C1 LRKOXEUNEVGZCA-UHFFFAOYSA-N 0.000 description 1
- SJARQJSJJCDCQF-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxy-4-methylcyclohexyl)acetic acid Chemical compound C1CC(C)CCC1(O)C(C(O)=O)C1=CC=CC(Cl)=C1 SJARQJSJJCDCQF-UHFFFAOYSA-N 0.000 description 1
- NPCYVMDTVZESBI-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxycyclohexyl)-1-(4-pyrrolidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1CC(N2CCCC2)CCN1C(=O)C(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 NPCYVMDTVZESBI-UHFFFAOYSA-N 0.000 description 1
- FRSCGOXMFCBAGH-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-(1-hydroxycyclohexyl)-1-piperidin-1-ylethanone Chemical compound C1CCCCN1C(=O)C(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 FRSCGOXMFCBAGH-UHFFFAOYSA-N 0.000 description 1
- AATUGVZHSMNMPK-UHFFFAOYSA-N 2-(3-chlorophenyl)-3,3-dicyclopropyl-3-hydroxypropanoic acid Chemical compound C1CC1C(O)(C1CC1)C(C(=O)O)C1=CC=CC(Cl)=C1 AATUGVZHSMNMPK-UHFFFAOYSA-N 0.000 description 1
- VCLHDECBBGLREG-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-ethyl-3-hydroxypentanoic acid Chemical compound CCC(O)(CC)C(C(O)=O)C1=CC=CC(Cl)=C1 VCLHDECBBGLREG-UHFFFAOYSA-N 0.000 description 1
- YRFBZAHYMOSSGX-UHFFFAOYSA-N 2-(3-fluoro-4-hydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(O)C(F)=C1 YRFBZAHYMOSSGX-UHFFFAOYSA-N 0.000 description 1
- QNOIQYUGBDXHDQ-UHFFFAOYSA-N 2-(3-fluoro-4-phenylmethoxyphenyl)-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1F)=CC=C1OCC1=CC=CC=C1 QNOIQYUGBDXHDQ-UHFFFAOYSA-N 0.000 description 1
- AYCIHUSEBJLTBF-UHFFFAOYSA-N 2-(3-methoxy-4-phenylmethoxyphenyl)acetic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1OCC1=CC=CC=C1 AYCIHUSEBJLTBF-UHFFFAOYSA-N 0.000 description 1
- LEMRHTTWKDVQEI-UHFFFAOYSA-N 2-(3-phenoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 LEMRHTTWKDVQEI-UHFFFAOYSA-N 0.000 description 1
- IDGZOJABEZWGFT-UHFFFAOYSA-N 2-(4-hydroxy-1-methylpiperidin-4-yl)-1-morpholin-4-yl-2-naphthalen-2-ylethanone Chemical compound C1CN(C)CCC1(O)C(C=1C=C2C=CC=CC2=CC=1)C(=O)N1CCOCC1 IDGZOJABEZWGFT-UHFFFAOYSA-N 0.000 description 1
- QUYVGPXEJNBRPE-UHFFFAOYSA-N 2-(4-hydroxy-1-methylpiperidin-4-yl)-2-naphthalen-2-ylacetic acid Chemical compound C1CN(C)CCC1(O)C(C(O)=O)C1=CC=C(C=CC=C2)C2=C1 QUYVGPXEJNBRPE-UHFFFAOYSA-N 0.000 description 1
- QKZVRCNQAQLAJL-UHFFFAOYSA-N 2-(4-tert-butyl-1-hydroxycyclohexyl)-2-naphthalen-1-ylacetic acid Chemical compound C1CC(C(C)(C)C)CCC1(O)C(C(O)=O)C1=CC=CC2=CC=CC=C12 QKZVRCNQAQLAJL-UHFFFAOYSA-N 0.000 description 1
- HQIXXXJTRKTFIF-UHFFFAOYSA-N 2-(5-bromothiophen-2-yl)acetic acid Chemical compound OC(=O)CC1=CC=C(Br)S1 HQIXXXJTRKTFIF-UHFFFAOYSA-N 0.000 description 1
- LECLHWWOMUWTCA-UHFFFAOYSA-N 2-(5-bromothiophen-3-yl)acetic acid Chemical compound OC(=O)CC1=CSC(Br)=C1 LECLHWWOMUWTCA-UHFFFAOYSA-N 0.000 description 1
- PFZQOMLBCHGLQZ-UHFFFAOYSA-N 2-(5-chlorothiophen-3-yl)acetic acid Chemical compound OC(=O)CC1=CSC(Cl)=C1 PFZQOMLBCHGLQZ-UHFFFAOYSA-N 0.000 description 1
- HQKKDFBWDIRZOZ-UHFFFAOYSA-N 2-(5-methoxy-1-benzothiophen-2-yl)acetic acid Chemical compound COC1=CC=C2SC(CC(O)=O)=CC2=C1 HQKKDFBWDIRZOZ-UHFFFAOYSA-N 0.000 description 1
- GQWMNVOVQZIPJC-UHFFFAOYSA-N 2-(trifluoromethoxy)phenol Chemical compound OC1=CC=CC=C1OC(F)(F)F GQWMNVOVQZIPJC-UHFFFAOYSA-N 0.000 description 1
- ZOQOPXVJANRGJZ-UHFFFAOYSA-N 2-(trifluoromethyl)phenol Chemical compound OC1=CC=CC=C1C(F)(F)F ZOQOPXVJANRGJZ-UHFFFAOYSA-N 0.000 description 1
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 1
- IMQJLHQFJGCPDA-JTZLXEIQSA-N 2-[(3r)-1-hydroxy-3-methylcyclopentyl]-2-[3-(trifluoromethoxy)phenyl]acetic acid Chemical compound C1[C@H](C)CCC1(O)C(C(O)=O)C1=CC=CC(OC(F)(F)F)=C1 IMQJLHQFJGCPDA-JTZLXEIQSA-N 0.000 description 1
- LXMOMZXGDAAVFR-UHFFFAOYSA-N 2-[2-(4-aminopiperidin-1-yl)-1-(3-chlorophenyl)ethyl]cyclohexan-1-ol Chemical compound C1CC(N)CCN1CC(C=1C=C(Cl)C=CC=1)C1C(O)CCCC1 LXMOMZXGDAAVFR-UHFFFAOYSA-N 0.000 description 1
- JPPVWMHZDMLCHP-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]ethanimidamide Chemical compound NC(=N)CC1=CC=CC(OC(F)(F)F)=C1 JPPVWMHZDMLCHP-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- YMKMGFQFNWPASD-UHFFFAOYSA-N 2-[3-chloro-4-[(2-methoxyphenyl)methoxy]phenyl]-2-(1-hydroxycyclohexyl)acetic acid Chemical compound COC1=CC=CC=C1COC1=CC=C(C(C(O)=O)C2(O)CCCCC2)C=C1Cl YMKMGFQFNWPASD-UHFFFAOYSA-N 0.000 description 1
- DUJNGFLQNAQHEJ-UHFFFAOYSA-N 2-[3-chloro-4-[(3-methoxyphenyl)methoxy]phenyl]acetic acid Chemical compound COC1=CC=CC(COC=2C(=CC(CC(O)=O)=CC=2)Cl)=C1 DUJNGFLQNAQHEJ-UHFFFAOYSA-N 0.000 description 1
- SUFVSGPQUUMMDC-UHFFFAOYSA-N 2-[4-(2-phenylethoxy)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1OCCC1=CC=CC=C1 SUFVSGPQUUMMDC-UHFFFAOYSA-N 0.000 description 1
- OVUTXCURKKXBFM-UHFFFAOYSA-N 2-[4-(2-phenylethyl)phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCC1=CC=CC=C1 OVUTXCURKKXBFM-UHFFFAOYSA-N 0.000 description 1
- ARKZPBIBNCNIMH-UHFFFAOYSA-N 2-[4-(cyclohexylmethoxy)phenyl]-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1OCC1CCCCC1 ARKZPBIBNCNIMH-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- PWHMGGFQTXMTKE-UHFFFAOYSA-N 2-[4-[2-(4-fluorophenyl)ethoxy]phenyl]-2-(1-hydroxycyclohexyl)acetic acid Chemical compound C1CCCCC1(O)C(C(=O)O)C(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 PWHMGGFQTXMTKE-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- GHGJHJPAQJNYHZ-UHFFFAOYSA-N 2-cyclohexylethanimidamide Chemical compound NC(=N)CC1CCCCC1 GHGJHJPAQJNYHZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VTWYQAQIXXAXOR-UHFFFAOYSA-N 2-methylsulfonylpropane Chemical group CC(C)S(C)(=O)=O VTWYQAQIXXAXOR-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- GYGYLGPQOCOYHH-UHFFFAOYSA-N 2-propan-2-ylxanthen-9-one Chemical group C1=CC=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=C1 GYGYLGPQOCOYHH-UHFFFAOYSA-N 0.000 description 1
- RCNOGGGBSSVMAS-UHFFFAOYSA-N 2-thiophen-3-ylacetic acid Chemical compound OC(=O)CC=1C=CSC=1 RCNOGGGBSSVMAS-UHFFFAOYSA-N 0.000 description 1
- AFEFRXAPJRCTOW-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-naphthalen-1-one Chemical compound C1CCCC2C(=O)CCCC21 AFEFRXAPJRCTOW-UHFFFAOYSA-N 0.000 description 1
- YWKYYQJHIJYHII-UHFFFAOYSA-N 3,4-dibenzylbenzaldehyde Chemical compound C=1C=CC=CC=1CC1=CC(C=O)=CC=C1CC1=CC=CC=C1 YWKYYQJHIJYHII-UHFFFAOYSA-N 0.000 description 1
- QOTAQTRFJWLFCR-UHFFFAOYSA-N 3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(4-methoxycyclohexyl)methanone Chemical compound C1CC(OC)CCC1C(=O)C1=CC=C(N=C2C(CCCO2)=C2)C2=C1 QOTAQTRFJWLFCR-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
- XLDOHHDYBPSSBN-UHFFFAOYSA-N 3-ethyl-3-hydroxy-2-naphthalen-1-ylpentanoic acid Chemical compound C1=CC=C2C(C(C(O)=O)C(O)(CC)CC)=CC=CC2=C1 XLDOHHDYBPSSBN-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XFCRJSLGFAPBKE-UHFFFAOYSA-N 4-(2,2-dibromoethenyl)-1-phenylmethoxy-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(C=C(Br)Br)=CC=C1OCC1=CC=CC=C1 XFCRJSLGFAPBKE-UHFFFAOYSA-N 0.000 description 1
- LRWUBGJDMZNXHP-UHFFFAOYSA-N 4-(4-aminopiperidin-1-yl)-3-(3-chlorophenyl)-2-methylbutan-2-ol;dihydrochloride Chemical compound Cl.Cl.C=1C=CC(Cl)=CC=1C(C(C)(O)C)CN1CCC(N)CC1 LRWUBGJDMZNXHP-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- ILBDCOLCHNVWNS-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]benzoic acid Chemical compound CC(C)(C)OC(=O)C1=CC=C(C(O)=O)C=C1 ILBDCOLCHNVWNS-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- LCLFQCSZKTUNHC-UHFFFAOYSA-N 4-[2-(2-bromophenyl)-2-(1-hydroxycyclohexyl)ethyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1CC(C1(O)CCCCC1)C1=CC=CC=C1Br LCLFQCSZKTUNHC-UHFFFAOYSA-N 0.000 description 1
- UNUYWJNEAJKDKV-UHFFFAOYSA-N 4-[2-(benzylamino)-1-(3,4-dichlorophenyl)ethyl]-1-methylpiperidin-4-ol;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCC1(O)C(C=1C=C(Cl)C(Cl)=CC=1)CNCC1=CC=CC=C1 UNUYWJNEAJKDKV-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- SKEJAYFILBSZBS-UHFFFAOYSA-N 4-bromo-2-(2,2-dibromoethenyl)thiophene Chemical compound BrC(Br)=CC1=CC(Br)=CS1 SKEJAYFILBSZBS-UHFFFAOYSA-N 0.000 description 1
- OKSDJGWHKXFVME-UHFFFAOYSA-N 4-ethylcyclohexan-1-one Chemical compound CCC1CCC(=O)CC1 OKSDJGWHKXFVME-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZLMUFCNWTPSOSN-UHFFFAOYSA-N 4-hydroxy-3-(trifluoromethyl)benzaldehyde Chemical compound OC1=CC=C(C=O)C=C1C(F)(F)F ZLMUFCNWTPSOSN-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZEYSHALLPAKUHG-UHFFFAOYSA-N 4-methoxypiperidine Chemical compound COC1CCNCC1 ZEYSHALLPAKUHG-UHFFFAOYSA-N 0.000 description 1
- JQXVCFQMFUNCHZ-UHFFFAOYSA-N 4-phenylmethoxy-3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 JQXVCFQMFUNCHZ-UHFFFAOYSA-N 0.000 description 1
- ZVTWZSXLLMNMQC-UHFFFAOYSA-N 4-phenylmethoxybenzaldehyde Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC=C1 ZVTWZSXLLMNMQC-UHFFFAOYSA-N 0.000 description 1
- 125000004937 4H-carbazolyl group Chemical group C=1(C=CCC2=C3C=CC=CC3=NC12)* 0.000 description 1
- ABGKKZSURWGNON-UHFFFAOYSA-N 5-[1-(1-hydroxycyclohexyl)-2-piperazin-1-ylethyl]-2-phenylmethoxybenzonitrile Chemical compound C1CNCCN1CC(C=1C=C(C(OCC=2C=CC=CC=2)=CC=1)C#N)C1(O)CCCCC1 ABGKKZSURWGNON-UHFFFAOYSA-N 0.000 description 1
- NZLGFGIYAYGSJJ-UHFFFAOYSA-M 5-benzyl-5-ethyl-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-ium;bromide Chemical compound [Br-].C1N(C)CCC2=C1C1=CC=CC=C1[N+]2(CC)CC1=CC=CC=C1 NZLGFGIYAYGSJJ-UHFFFAOYSA-M 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- XADGZBXFWQHBDB-UHFFFAOYSA-N 5-ethylfuran-2-carbaldehyde Chemical compound CCC1=CC=C(C=O)O1 XADGZBXFWQHBDB-UHFFFAOYSA-N 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- VZBLASFLFFMMCM-UHFFFAOYSA-N 6-methoxynaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(OC)=CC=C21 VZBLASFLFFMMCM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010049589 Afterbirth pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- YJBQWQQDHDJLDH-UHFFFAOYSA-N BrC1=CC=C(C=C1)C(CC1CCN(CC1)C(=O)O)C1(CCCCC1)O Chemical compound BrC1=CC=C(C=C1)C(CC1CCN(CC1)C(=O)O)C1(CCCCC1)O YJBQWQQDHDJLDH-UHFFFAOYSA-N 0.000 description 1
- WHMOVZYQHATUTA-UHFFFAOYSA-N BrC=1C=C(C=CC1)C(CN1CCC(CC1)C)C(CCC)(CCC)O Chemical compound BrC=1C=C(C=CC1)C(CN1CCC(CC1)C)C(CCC)(CCC)O WHMOVZYQHATUTA-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- UYKUZMHWFAHIDN-UHFFFAOYSA-N C#CC1=CC(=CC=C1)C(CN2CCCCC2)C3(CCCCC3)O Chemical compound C#CC1=CC(=CC=C1)C(CN2CCCCC2)C3(CCCCC3)O UYKUZMHWFAHIDN-UHFFFAOYSA-N 0.000 description 1
- KQFNAKVWGAXPIA-UHFFFAOYSA-N C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CC(=CC=C1)Br)C(=O)O Chemical compound C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CC(=CC=C1)Br)C(=O)O KQFNAKVWGAXPIA-UHFFFAOYSA-N 0.000 description 1
- VCKNLHCBZZQSTH-UHFFFAOYSA-N C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CC=C(C=C1)Br)C(=O)O Chemical compound C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CC=C(C=C1)Br)C(=O)O VCKNLHCBZZQSTH-UHFFFAOYSA-N 0.000 description 1
- ZDWHHUZUGWEDJN-UHFFFAOYSA-N C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CSC(=C1)Cl)C(=O)O Chemical compound C(C)(C)(C)C1N(CCC(C1)CC(C1(CCCCC1)O)C1=CSC(=C1)Cl)C(=O)O ZDWHHUZUGWEDJN-UHFFFAOYSA-N 0.000 description 1
- PCTHQMLIPZGPDF-UHFFFAOYSA-N C(C)(C)(C)C=1SC2=C(C1CC(=O)O)C=C(C=C2)Cl Chemical compound C(C)(C)(C)C=1SC2=C(C1CC(=O)O)C=C(C=C2)Cl PCTHQMLIPZGPDF-UHFFFAOYSA-N 0.000 description 1
- UEILAJUDSDEUDL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)C(C)(C)C.ClC=1SC(=CC1C=CC1CCNCC1)Cl Chemical compound C(C)(C)(C)OC(=O)C(C)(C)C.ClC=1SC(=CC1C=CC1CCNCC1)Cl UEILAJUDSDEUDL-UHFFFAOYSA-N 0.000 description 1
- LUPIANACOXPWTD-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)C1=C(C(=CC=2C3=CC=CC=C3CC12)C1=CC=C(C=C1)Br)CCC1(CCC1)O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C1=C(C(=CC=2C3=CC=CC=C3CC12)C1=CC=C(C=C1)Br)CCC1(CCC1)O LUPIANACOXPWTD-UHFFFAOYSA-N 0.000 description 1
- RICBLACJYONYGM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)C=C(C1(CCCCC1)O)C1=CC=C(C=C1)Br Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C=C(C1(CCCCC1)O)C1=CC=C(C=C1)Br RICBLACJYONYGM-UHFFFAOYSA-N 0.000 description 1
- CPAGKXHRYVKWQJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CC(C1(CCCCC1)O)C1=CSC(=C1)Cl Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CC(C1(CCCCC1)O)C1=CSC(=C1)Cl CPAGKXHRYVKWQJ-UHFFFAOYSA-N 0.000 description 1
- SYQJOBNNBXGUDP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CC(C1(CCCCC1)O)C=1C=C(C(=CC1)OC)C1=CC(=C(C=C1)Cl)Cl Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CC(C1(CCCCC1)O)C=1C=C(C(=CC1)OC)C1=CC(=C(C=C1)Cl)Cl SYQJOBNNBXGUDP-UHFFFAOYSA-N 0.000 description 1
- OHCUINSOCFYHAV-UHFFFAOYSA-N C(C)(C)(C)OC(NC1CCN(CC1)C=C(C1CCCCCC1)C1=CC(=CC=C1)Cl)=O Chemical compound C(C)(C)(C)OC(NC1CCN(CC1)C=C(C1CCCCCC1)C1=CC(=CC=C1)Cl)=O OHCUINSOCFYHAV-UHFFFAOYSA-N 0.000 description 1
- FDGYCLHAPHNPJO-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=C(C=C1)C(=CN1CCC(CC1)O)C1(CCCCC1)O)Cl Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C=C1)C(=CN1CCC(CC1)O)C1(CCCCC1)O)Cl FDGYCLHAPHNPJO-UHFFFAOYSA-N 0.000 description 1
- LTJUGCSJBVCVNX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCNCC1(C(=O)O)C(=O)O Chemical compound CC(C)(C)OC(=O)N1CCNCC1(C(=O)O)C(=O)O LTJUGCSJBVCVNX-UHFFFAOYSA-N 0.000 description 1
- LGEPQWIXUIVSIK-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1C=C(C1(CCCCC1)O)C1=CC(Cl)=CC=C1)=O Chemical class CC(C)(C)OC(NC(CC1)CCN1C=C(C1(CCCCC1)O)C1=CC(Cl)=CC=C1)=O LGEPQWIXUIVSIK-UHFFFAOYSA-N 0.000 description 1
- YHYQLHQYEFNZNI-UHFFFAOYSA-N CCC(C(C1=CC(=CC=C1)Cl)C(C)C2(CCCCC2)O)N3CCCCC3 Chemical compound CCC(C(C1=CC(=CC=C1)Cl)C(C)C2(CCCCC2)O)N3CCCCC3 YHYQLHQYEFNZNI-UHFFFAOYSA-N 0.000 description 1
- KSLPNQPILAGPEM-UHFFFAOYSA-N CCCC(C(C)(C)C)C(=O)OC(C)(C)C Chemical compound CCCC(C(C)(C)C)C(=O)OC(C)(C)C KSLPNQPILAGPEM-UHFFFAOYSA-N 0.000 description 1
- 101100087393 Caenorhabditis elegans ran-2 gene Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GGYQEWYKJUTUBF-UHFFFAOYSA-N Cl.Cl.C(C1=CC=CC=C1)OC=1C=C(C=CC1)C(CN1CCC(CC1)C)C1(CCC1)O Chemical compound Cl.Cl.C(C1=CC=CC=C1)OC=1C=C(C=CC1)C(CN1CCC(CC1)C)C1(CCC1)O GGYQEWYKJUTUBF-UHFFFAOYSA-N 0.000 description 1
- RZSJOMKYIMAJNP-UHFFFAOYSA-N Cl.Cl.C1(CCCCC1)=O Chemical compound Cl.Cl.C1(CCCCC1)=O RZSJOMKYIMAJNP-UHFFFAOYSA-N 0.000 description 1
- XFZJNKCCIPUTAP-UHFFFAOYSA-N Cl.Cl.CC1CCN(CC1)CC(C1=CC=CC2=CC=CC=C12)C1(CCC1)O Chemical compound Cl.Cl.CC1CCN(CC1)CC(C1=CC=CC2=CC=CC=C12)C1(CCC1)O XFZJNKCCIPUTAP-UHFFFAOYSA-N 0.000 description 1
- XAWKYLWUXQVVIR-UHFFFAOYSA-N Cl.Cl.CC1CCNCC1 Chemical compound Cl.Cl.CC1CCNCC1 XAWKYLWUXQVVIR-UHFFFAOYSA-N 0.000 description 1
- HRKCTESEMNWGHT-UHFFFAOYSA-N Cl.Cl.ClC=1C=C(C=CC1)C(C(C)(O)C)CN1CCC(CC1)C Chemical compound Cl.Cl.ClC=1C=C(C=CC1)C(C(C)(O)C)CN1CCC(CC1)C HRKCTESEMNWGHT-UHFFFAOYSA-N 0.000 description 1
- DBFRWVLUHZIJHV-UHFFFAOYSA-N ClC=1C=C(C=CC1)C(CC1=C(C=2CC3=CC=CC=C3C2C=C1)N1CCC(CC1)NC(O)=O)C(C)(C)O Chemical compound ClC=1C=C(C=CC1)C(CC1=C(C=2CC3=CC=CC=C3C2C=C1)N1CCC(CC1)NC(O)=O)C(C)(C)O DBFRWVLUHZIJHV-UHFFFAOYSA-N 0.000 description 1
- PMCQOBGBDVZGHP-UHFFFAOYSA-N ClC=1C=C(C=CC1)C(CN1C(CC(CC1)N)C)C1CCCCC1 Chemical compound ClC=1C=C(C=CC1)C(CN1C(CC(CC1)N)C)C1CCCCC1 PMCQOBGBDVZGHP-UHFFFAOYSA-N 0.000 description 1
- PHTPMIGIRKMLJK-UHFFFAOYSA-N ClC=1C=C(C=CC1Cl)C(=CN1CCC(CC1)NC(O)=O)C1(CCCCC1)O Chemical compound ClC=1C=C(C=CC1Cl)C(=CN1CCC(CC1)NC(O)=O)C1(CCCCC1)O PHTPMIGIRKMLJK-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- PCEDBMKDBRXETF-UHFFFAOYSA-N N1CCCCC1.C(CCC)OC(=O)N Chemical group N1CCCCC1.C(CCC)OC(=O)N PCEDBMKDBRXETF-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- ZRMQOIPUQQWQAK-UHFFFAOYSA-N OC1(CC(CC(C1)(C)C)(C)C)CC(=O)O Chemical compound OC1(CC(CC(C1)(C)C)(C)C)CC(=O)O ZRMQOIPUQQWQAK-UHFFFAOYSA-N 0.000 description 1
- OZYWCJNWZCYGCQ-UHFFFAOYSA-N OCCC(=O)O.ClC=1C=C(C=CC1)C1CC1C1CC1 Chemical compound OCCC(=O)O.ClC=1C=C(C=CC1)C1CC1C1CC1 OZYWCJNWZCYGCQ-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034240 Pelvic congestion Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 241000546339 Trioxys Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- AIJCNTOYZPKURP-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1OC(F)(F)F AIJCNTOYZPKURP-UHFFFAOYSA-N 0.000 description 1
- LPMBWLGTDUWXDW-UHFFFAOYSA-N [5-(4-bromophenyl)-5-hydroxy-5-phenylpent-2-ynyl]-diethylazanium;chloride Chemical compound Cl.C=1C=C(Br)C=CC=1C(O)(CC#CCN(CC)CC)C1=CC=CC=C1 LPMBWLGTDUWXDW-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- SVPQRBCSONEAHF-UHFFFAOYSA-N ac1mxsc9 Chemical compound C1CCCCC1N=C1C=C2N3C(CCCC4)=C4CC4CCCCC43N=C2C=C1 SVPQRBCSONEAHF-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- MONCQVLYCHAKMU-UHFFFAOYSA-N azane;cyclohexanol;hydrochloride Chemical compound N.Cl.OC1CCCCC1 MONCQVLYCHAKMU-UHFFFAOYSA-N 0.000 description 1
- FLNKWZNWHZDGRT-UHFFFAOYSA-N azane;dihydrochloride Chemical compound [NH4+].[NH4+].[Cl-].[Cl-] FLNKWZNWHZDGRT-UHFFFAOYSA-N 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 208000003770 biliary dyskinesia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- LOXORFRCPXUORP-UHFFFAOYSA-N bromo-Cycloheptane Chemical compound BrC1CCCCCC1 LOXORFRCPXUORP-UHFFFAOYSA-N 0.000 description 1
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- LMSNZLCSZWZZGU-UHFFFAOYSA-N butan-1-ol;hydrochloride Chemical compound Cl.CCCCO LMSNZLCSZWZZGU-UHFFFAOYSA-N 0.000 description 1
- ASSQXZCUYOADEH-UHFFFAOYSA-N butan-2-yl carbamate Chemical compound CCC(C)OC(N)=O ASSQXZCUYOADEH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LVTLACMYEGMHBZ-UHFFFAOYSA-N butyl 2-aminobutanoate Chemical group CCCCOC(=O)C(N)CC LVTLACMYEGMHBZ-UHFFFAOYSA-N 0.000 description 1
- SOCLSWGEBTVYPT-UHFFFAOYSA-N butyl N-[1-[2-(3-bromophenyl)-2-(1-hydroxycyclohexyl)ethyl]piperidin-4-yl]carbamate Chemical compound CCCCOC(=O)NC1CCN(CC(c2cccc(Br)c2)C2(O)CCCCC2)CC1 SOCLSWGEBTVYPT-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NIRLALXKRWOWQS-UHFFFAOYSA-N cyclobutanol hydrochloride Chemical compound Cl.C1(CCC1)O NIRLALXKRWOWQS-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- DCFDVJPDXYGCOK-UHFFFAOYSA-N cyclohex-3-ene-1-carbaldehyde Chemical compound O=CC1CCC=CC1 DCFDVJPDXYGCOK-UHFFFAOYSA-N 0.000 description 1
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 1
- ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohexene oxide Natural products O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 1
- IIRFCWANHMSDCG-UHFFFAOYSA-N cyclooctanone Chemical compound O=C1CCCCCCC1 IIRFCWANHMSDCG-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- PVFTVTSMZMQOLM-UHFFFAOYSA-N cyclopropane;formaldehyde Chemical compound O=C.C1CC1 PVFTVTSMZMQOLM-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZQPSLFXJMBAJGL-UHFFFAOYSA-N formaldehyde quinoline Chemical compound O=C.N1=CC=CC2=CC=CC=C21 ZQPSLFXJMBAJGL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000012789 harvest method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- LASAPRSWJLHSBD-UHFFFAOYSA-N heptan-1-ol dihydrochloride Chemical compound Cl.Cl.C(CCCCCC)O LASAPRSWJLHSBD-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 102000055827 human SLC6A2 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- QSPAEUKIWTXLSC-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li+].CC(C)NC(C)C QSPAEUKIWTXLSC-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- LBBMOAOCCQOIAQ-UHFFFAOYSA-N methoxy(phenyl)borinic acid Chemical compound COB(O)C1=CC=CC=C1 LBBMOAOCCQOIAQ-UHFFFAOYSA-N 0.000 description 1
- OEJGHZYMFABHKU-UHFFFAOYSA-N methyl 2-hydroxy-4-oxo-4-(4-propan-2-ylphenyl)-2-(trifluoromethyl)butanoate Chemical compound COC(=O)C(O)(C(F)(F)F)CC(=O)C1=CC=C(C(C)C)C=C1 OEJGHZYMFABHKU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- NWJUMMHVDMNYMJ-UHFFFAOYSA-N n-benzyl-1,1,1-trifluoromethanamine Chemical compound FC(F)(F)NCC1=CC=CC=C1 NWJUMMHVDMNYMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- FHTGZDVYPCEHFQ-UHFFFAOYSA-N n-methylpiperidin-4-amine Chemical compound CNC1CCNCC1 FHTGZDVYPCEHFQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- PKVRJCUKSNFIBN-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 PKVRJCUKSNFIBN-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NSNNIMABMDKABJ-UHFFFAOYSA-N piperidin-4-ol;dihydrochloride Chemical compound Cl.Cl.OC1CCNCC1 NSNNIMABMDKABJ-UHFFFAOYSA-N 0.000 description 1
- VKCORPXOKYDINR-UHFFFAOYSA-N piperidin-4-ol;hydrochloride Chemical compound [Cl-].OC1CC[NH2+]CC1 VKCORPXOKYDINR-UHFFFAOYSA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- MTLHWOJJIGFLDC-UHFFFAOYSA-N pyridin-4-amine;dihydrochloride Chemical compound Cl.Cl.NC1=CC=NC=C1 MTLHWOJJIGFLDC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- KLIXNCCLUDOLIT-UHFFFAOYSA-N tert-butyl 4-[2-(1-hydroxycyclohexyl)-2-[4-phenylmethoxy-3-(trifluoromethyl)phenyl]acetyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C(C1(O)CCCCC1)C(C=C1C(F)(F)F)=CC=C1OCC1=CC=CC=C1 KLIXNCCLUDOLIT-UHFFFAOYSA-N 0.000 description 1
- GFVLXRLCOSUNJL-UHFFFAOYSA-N tert-butyl 4-[2-(1-hydroxycyclohexyl)-2-[4-phenylmethoxy-3-(trifluoromethyl)phenyl]acetyl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C(C(C1(CCCCC1)O)C1=CC(=C(C=C1)OCC1=CC=CC=C1)C(F)(F)F)=O GFVLXRLCOSUNJL-UHFFFAOYSA-N 0.000 description 1
- JBAIKXHAAOEGOD-UHFFFAOYSA-N tert-butyl 4-[2-(1-hydroxycyclohexyl)-2-[4-phenylmethoxy-3-(trifluoromethyl)phenyl]ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C(C=C1C(F)(F)F)=CC=C1OCC1=CC=CC=C1 JBAIKXHAAOEGOD-UHFFFAOYSA-N 0.000 description 1
- DJGARZFRFQBQBL-UHFFFAOYSA-N tert-butyl 4-[2-(1-hydroxycyclohexyl)-2-quinolin-3-ylethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=CN=C(C=CC=C2)C2=C1 DJGARZFRFQBQBL-UHFFFAOYSA-N 0.000 description 1
- PPUIAGGCRRCHTL-UHFFFAOYSA-N tert-butyl 4-[2-(2,5-dichlorothiophen-3-yl)-2-(1-hydroxycyclohexyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=C(Cl)SC(Cl)=C1 PPUIAGGCRRCHTL-UHFFFAOYSA-N 0.000 description 1
- WYOLSVWTEXXBPR-UHFFFAOYSA-N tert-butyl 4-[2-(3-bromophenyl)-2-(1-hydroxycyclobutyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCC1)C1=CC=CC(Br)=C1 WYOLSVWTEXXBPR-UHFFFAOYSA-N 0.000 description 1
- GXFBHSLODPZSRG-UHFFFAOYSA-N tert-butyl 4-[2-(3-bromophenyl)-2-(1-hydroxycyclohexyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Br)=C1 GXFBHSLODPZSRG-UHFFFAOYSA-N 0.000 description 1
- LPZIKBVTGDEXCT-UHFFFAOYSA-N tert-butyl 4-[2-(4-bromophenyl)-2-(1-hydroxycyclohexyl)ethyl]piperazine-1-carboxylate Chemical class C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=C(Br)C=C1 LPZIKBVTGDEXCT-UHFFFAOYSA-N 0.000 description 1
- PEDVAQUYADGZDW-UHFFFAOYSA-N tert-butyl 4-[2-[4-(2-fluorophenyl)phenyl]-2-(1-hydroxycyclohexyl)ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=C(C=2C(=CC=CC=2)F)C=C1 PEDVAQUYADGZDW-UHFFFAOYSA-N 0.000 description 1
- LOBVMCLXKOKIAS-UHFFFAOYSA-N tert-butyl 4-[2-[4-phenylmethoxy-3-(trifluoromethoxy)phenyl]ethenyl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C=CC1=CC(=C(C=C1)OCC1=CC=CC=C1)OC(F)(F)F LOBVMCLXKOKIAS-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-MRVPVSSYSA-N tert-butyl n-[(3r)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCNC1 WUOQXNWMYLFAHT-MRVPVSSYSA-N 0.000 description 1
- ZKHHXYQDYAYXDM-UHFFFAOYSA-N tert-butyl n-[1-[2-(3,4-dichlorophenyl)-2-(1-hydroxycyclohexyl)ethyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC(C1(O)CCCCC1)C1=CC=C(Cl)C(Cl)=C1 ZKHHXYQDYAYXDM-UHFFFAOYSA-N 0.000 description 1
- IUHRDCVRNBKBMO-UHFFFAOYSA-N tert-butyl n-pyrrolidin-1-ylcarbamate Chemical compound CC(C)(C)OC(=O)NN1CCCC1 IUHRDCVRNBKBMO-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- SCSLUABEVMLYEA-UHFFFAOYSA-N tert-butyl pentanoate Chemical group CCCCC(=O)OC(C)(C)C SCSLUABEVMLYEA-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 208000012720 thalamic disease Diseases 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- JGOIIPRSFZFFHG-UHFFFAOYSA-N trimethyl(2-tributylstannylethynyl)silane Chemical compound CCCC[Sn](CCCC)(CCCC)C#C[Si](C)(C)C JGOIIPRSFZFFHG-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51081103P | 2003-10-14 | 2003-10-14 | |
| US56144704P | 2004-04-12 | 2004-04-12 | |
| US57005604P | 2004-05-11 | 2004-05-11 | |
| US10/963,064 US7419980B2 (en) | 2003-10-14 | 2004-10-12 | Fused-aryl and heteroaryl derivatives and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200526603A true TW200526603A (en) | 2005-08-16 |
Family
ID=34468484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093131005A TW200526603A (en) | 2003-10-14 | 2004-10-13 | Fused-aryl and heteroaryl derivatives and methods of their use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7419980B2 (enExample) |
| EP (1) | EP1673090A1 (enExample) |
| JP (1) | JP2007508393A (enExample) |
| AR (1) | AR046179A1 (enExample) |
| AU (1) | AU2004281734A1 (enExample) |
| BR (1) | BRPI0415276A (enExample) |
| CA (1) | CA2549733A1 (enExample) |
| MX (1) | MXPA06003879A (enExample) |
| PA (1) | PA8615201A1 (enExample) |
| TW (1) | TW200526603A (enExample) |
| WO (1) | WO2005037283A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7414052B2 (en) * | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| US20070021488A1 (en) * | 2005-07-21 | 2007-01-25 | Wyeth | Method for treating nervous system disorders and conditions |
| WO2007067575A2 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for preparing substituted aryl cycloalkanol derivatives |
| US7994190B2 (en) | 2006-11-01 | 2011-08-09 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2010016554A1 (ja) * | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 環状アミン化合物 |
| JP5806221B2 (ja) * | 2009-10-13 | 2015-11-10 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる3−置換化合物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454554A (en) * | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
| FR2035785A6 (enExample) * | 1969-03-28 | 1970-12-24 | Delalande Sa | |
| CS175831B1 (enExample) | 1974-12-17 | 1977-05-31 | ||
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
| PH18686A (en) | 1981-05-26 | 1985-08-29 | Merck & Co Inc | 1-(3 halo-2-pyridinyl) piperazine |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| ZA864772B (en) | 1985-07-02 | 1987-02-25 | Merrell Dow Pharma | Novel chemical compounds |
| CA1327795C (en) | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| US4826844A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols |
| ATE114467T1 (de) | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
| GB9021535D0 (en) | 1990-10-03 | 1990-11-14 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5502047A (en) * | 1993-03-22 | 1996-03-26 | Kavey; Neil B. | Treatment for insomnia |
| GB9306103D0 (en) | 1993-03-24 | 1993-05-12 | Wyeth John & Brother Ltd | Piperazine derivatives |
| CZ296263B6 (cs) | 1996-03-25 | 2006-02-15 | Eli Lilly And Company | Farmaceutická kompozice pro lécení bolesti a jejípouzití |
| WO1997044329A1 (en) | 1996-05-20 | 1997-11-27 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
| JPH10218866A (ja) | 1997-02-07 | 1998-08-18 | Pola Chem Ind Inc | ドーパミン再取り込み阻害剤 |
| KR20010015918A (ko) | 1998-03-02 | 2001-02-26 | 피터 지. 스트링거 | 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드 |
| ES2305606T3 (es) | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
| JP2003503450A (ja) * | 1999-07-01 | 2003-01-28 | ファルマシア・アンド・アップジョン・カンパニー | 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法 |
| HUP0301719A2 (hu) * | 2000-06-27 | 2003-09-29 | Taisho Pharmaceutical Co., Ltd. | Szorongásos neurózis vagy depresszió kezelésére szolgáló gyógyszerkészítmény és piperazinszármazékok |
| ATE369330T1 (de) | 2001-02-12 | 2007-08-15 | Wyeth Corp | O-desmethyl-venlafaxine succinat salz |
| EP1383495A1 (en) | 2001-03-29 | 2004-01-28 | Eli Lilly And Company | Duloxetine for treatment of hot flashes |
| EP1266659A1 (en) | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US20040259850A1 (en) | 2001-10-31 | 2004-12-23 | Alves Stephen E. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| EP1468990A4 (en) * | 2001-12-21 | 2006-01-04 | Taisho Pharmaceutical Co Ltd | PIPERAZINE DERIVATIVE |
| PL223471B1 (pl) | 2002-03-15 | 2016-10-31 | Cypress Bioscience Inc | Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| CA2495452A1 (en) | 2002-08-14 | 2004-02-26 | Pharmacia & Upjohn Company Llc | Use of reboxetine for the treatment of hot flashes |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
| US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
-
2004
- 2004-10-12 US US10/963,064 patent/US7419980B2/en not_active Expired - Fee Related
- 2004-10-13 CA CA002549733A patent/CA2549733A1/en not_active Abandoned
- 2004-10-13 EP EP04794905A patent/EP1673090A1/en not_active Withdrawn
- 2004-10-13 TW TW093131005A patent/TW200526603A/zh unknown
- 2004-10-13 AU AU2004281734A patent/AU2004281734A1/en not_active Abandoned
- 2004-10-13 BR BRPI0415276-0A patent/BRPI0415276A/pt not_active IP Right Cessation
- 2004-10-13 JP JP2006535599A patent/JP2007508393A/ja active Pending
- 2004-10-13 WO PCT/US2004/033671 patent/WO2005037283A1/en not_active Ceased
- 2004-10-13 MX MXPA06003879A patent/MXPA06003879A/es unknown
- 2004-10-14 PA PA20048615201A patent/PA8615201A1/es unknown
- 2004-10-14 AR ARP040103714A patent/AR046179A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06003879A (es) | 2006-07-03 |
| JP2007508393A (ja) | 2007-04-05 |
| BRPI0415276A (pt) | 2006-12-19 |
| AU2004281734A1 (en) | 2005-04-28 |
| PA8615201A1 (es) | 2005-05-10 |
| EP1673090A1 (en) | 2006-06-28 |
| US7419980B2 (en) | 2008-09-02 |
| US20050192283A1 (en) | 2005-09-01 |
| CA2549733A1 (en) | 2005-04-28 |
| WO2005037283A1 (en) | 2005-04-28 |
| AR046179A1 (es) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090227585A1 (en) | Substituted n-heterocycle derivatives and methods of their use | |
| US7550456B2 (en) | Substituted aryl cycloalkanoyl derivatives and methods of their use | |
| TW200526603A (en) | Fused-aryl and heteroaryl derivatives and methods of their use | |
| US7491723B2 (en) | Alkanol and cycloalkanol-amine derivatives and methods of their use | |
| US7524846B2 (en) | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | |
| US7402698B2 (en) | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | |
| CN1972920A (zh) | 用于治疗因单胺的再吸收而得以改善的包括血管舒缩症的病症的芳烷基哌嗪衍生物 |